Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

[Current standard in diagnostic and therapy of peripheral T-cell lymphoma].

Hopfinger G, Staber P.

Dtsch Med Wochenschr. 2019 Oct;144(20):1400-1404. doi: 10.1055/a-0597-7606. Epub 2019 Oct 8. German.

PMID:
31594013
2.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Review.

PMID:
31292114
3.

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators.

N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.

PMID:
30501490
4.

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2019 Mar;60(3):649-657. doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20.

PMID:
30234404
5.

Chimeric antigen receptor T‑cell therapy-a hematological success story.

Wohlfarth P, Worel N, Hopfinger G.

Memo. 2018;11(2):116-121. doi: 10.1007/s12254-018-0409-x. Epub 2018 Jun 6. Review.

6.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

7.

Extracorporeal photopheresis as second-line therapy for patients with acute graft-versus-host disease: does the number of cells treated matter?

Worel N, Lehner E, Führer H, Kalhs P, Rabitsch W, Mitterbauer M, Hopfinger G, Greinix HT.

Transfusion. 2018 Apr;58(4):1045-1053. doi: 10.1111/trf.14506. Epub 2018 Feb 15.

PMID:
29446444
8.

Torquetenovirus Dynamics and Immune Marker Properties in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective Longitudinal Study.

Wohlfarth P, Leiner M, Schoergenhofer C, Hopfinger G, Goerzer I, Puchhammer-Stoeckl E, Rabitsch W.

Biol Blood Marrow Transplant. 2018 Jan;24(1):194-199. doi: 10.1016/j.bbmt.2017.09.020. Epub 2017 Oct 12.

9.

First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Boidol B, Kornauth C, van der Kouwe E, Prutsch N, Kazianka L, Gültekin S, Hoermann G, Mayerhoefer ME, Hopfinger G, Hauswirth A, Panny M, Aretin MB, Hilgarth B, Sperr WR, Valent P, Simonitsch-Klupp I, Moriggl R, Merkel O, Kenner L, Jäger U, Kubicek S, Staber PB.

Blood. 2017 Dec 7;130(23):2499-2503. doi: 10.1182/blood-2017-05-785683. Epub 2017 Sep 27.

PMID:
28972014
10.

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S.

Leukemia. 2017 Dec;31(12):2833-2837. doi: 10.1038/leu.2017.246. Epub 2017 Aug 14. No abstract available.

PMID:
28804126
11.

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, von Tresckow J, Maurer C, Bergmann M, Seiler T, Lange E, Kneba M, Stilgenbauer S, Döhner H, Kiehl MG, Jäger U, Wendtner CM, Fischer K, Goede V, Hallek M, Eichhorst B, Hopfinger G.

Leukemia. 2017 Oct;31(10):2251-2253. doi: 10.1038/leu.2017.221. Epub 2017 Jul 12. No abstract available.

PMID:
28745332
12.

Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial.

Weiss L, Melchardt T, Egle A, Hopfinger G, Hackl H, Greil R, Barth J, Rummel M.

Ann Hematol. 2017 Jul;96(7):1155-1162. doi: 10.1007/s00277-017-3003-0. Epub 2017 Apr 30.

13.

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.

Kutsch N, Busch R, Bahlo J, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Wendtner CM, Maria Fink A, Fischer K, Hallek M, Eichhorst B.

Leuk Lymphoma. 2017 Feb;58(2):399-407. Epub 2016 Jun 29.

PMID:
27357445
14.

Cytomegalovirus reactivation and its clinical impact in patients with solid tumors.

Schlick K, Grundbichler M, Auberger J, Kern JM, Hell M, Hohla F, Hopfinger G, Greil R.

Infect Agent Cancer. 2015 Dec 3;10:45. doi: 10.1186/s13027-015-0039-4. eCollection 2015.

15.

VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions.

Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, Greil R, Hartmann TN, Hopfinger G.

Leuk Lymphoma. 2015;56(8):2465-7. doi: 10.3109/10428194.2014.999328. Epub 2015 Feb 9. No abstract available.

PMID:
25547652
16.

A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, Hackl H, Greil R, Pichler M, Egle A.

Br J Haematol. 2015 Jan;168(2):239-45. doi: 10.1111/bjh.13116. Epub 2014 Sep 19.

PMID:
25236324
17.

A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators.

Br J Haematol. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.

18.

Kasabach-Merritt phenomenon in hepatic angiosarcoma.

Habringer S, Boekstegers A, Weiss L, Hopfinger G, Meissnitzer T, Melchardt T, Egle A, Greil R.

Br J Haematol. 2014 Dec;167(5):716-8. doi: 10.1111/bjh.13049. Epub 2014 Jul 24. No abstract available.

PMID:
25060176
19.

A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation?

Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, Greil R, Hopfinger G.

Ann Hematol. 2015 Feb;94(2):345-6. doi: 10.1007/s00277-014-2162-5. Epub 2014 Jul 24. No abstract available.

PMID:
25055797
20.

Paraneoplastic phenomena and diagnostic challenges in angioimmunoblastic T-cell lymphoma (AITL): report of two cases and review of the literature.

Pircher A, Verdorfer I, Brunner A, Hopfinger G, Steurer M.

In Vivo. 2014 May-Jun;28(3):327-32. Review.

PMID:
24815834

Supplemental Content

Loading ...
Support Center